KORU Medical Systems's ROE % for the quarter that ended in Mar. 2026 was -19.01%. KORU Medical Systems's PB Ratio for the quarter that ended in Mar. 2026 was 11.77.
KORU Medical Systems's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -1.62%.
KORU Medical Systems ROE % Adjusted to Book Value Related Terms
KORU Medical Systems ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for KORU Medical Systems's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KORU Medical Systems ROE % Adjusted to Book Value Chart
KRMD vs EMBC, PDEX, SMTI: ROE % Adjusted to Book Value Comparison
For the Medical Instruments & Supplies subindustry, KORU Medical Systems's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KORU Medical Systems ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, KORU Medical Systems's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where KORU Medical Systems's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -1.62% mean?
KORU Medical Systems (KRMD) has a ROE % Adjusted to Book Value of -1.62% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on KORU Medical Systems and its competitors.
Is KORU Medical Systems' ROE % Adjusted to Book Value too high?
KORU Medical Systems' current ROE % Adjusted to Book Value is -1.62%. Overall, KORU Medical Systems has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does KORU Medical Systems' ROE % Adjusted to Book Value compare to EMBC and PDEX?
KORU Medical Systems' ROE % Adjusted to Book Value of -1.62% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on KORU Medical Systems and its competitors. KORU Medical Systems's current ROE % Adjusted to Book Value is -1.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KORU Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, KORU Medical Systems (KRMD) is currently considered Fairly Valued. The stock's GF Value™ is $4.08, compared to a current price of $4.43 — trading 8.6% above its estimated fair value. The current ROE % Adjusted to Book Value is -1.62%. KORU Medical Systems' overall GF Score™ is 76/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For KORU Medical Systems (KRMD), the current ROE % Adjusted to Book Value is -1.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KORU Medical Systems (KRMD) Overvalued in 2026?
Based on GuruFocus' analysis, KORU Medical Systems stock appears to be overvalued.
The current stock price of $4.43 is trading 8.6% above its estimated GF Value™ of $4.08.
GuruFocus considers KORU Medical Systems to be Fairly Valued.
Key valuation signals for KRMD:
ROE % Adjusted to Book Value: -1.62%
GF Value™: $4.08 vs. price of $4.43 (8.6% above fair value)
No single metric tells the full story. See the KRMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
76GF Score
Get the complete analysis for KRMD
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KRMD has been successfully added to your 
